Moderna says vaccine generates a strong immune response in kids under 6

• "This interim analysis showed a robust neutralizing antibody response in both age groups," Moderna said.
• The drugmaker also said that the majority of side effects for the approximately 6,900 children in the trials were "mild or moderate."
• Efficacy was 43.7% for children ages six months to two years and 37.5% in children ages two to six, per the statement.
• "The majority of cases were mild, and no severe COVID-19 disease was observed in either age group," the drugmaker said.

State of play: Moderna said it plans to submit its data to the Food and Drug Administration in the coming weeks.

• "Given the need for a vaccine against COVID-19 in infants and young children we are working with the U.S. FDA and regulators globally to submit these data as soon as possible," Moderna CEO Stéphane Bancel said in a statement.
• Moderna also announced that it has initiated submission for emergency use authorization of its COVID-19 vaccine in children ages 6 to 11 years old.

Go deeper: The kids' vaccine dilemma